Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China

• Main Authors: Yu Yang (Author), Liang Zhang (Author), Susanne Hartwig (Author), Peng Jiang (Author), Houyu Zhao (Author), Ruogu Meng (Author), Zhike Liu (Author), Zuoxiang Liu (Author), Keqin Ding (Author), Xuedan You (Author), Carol Koro (Author), Guozhang Xu (Author), Siyan Zhan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9-45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese women is lacking. Two post-marketing surveillance stu...